Literature DB >> 365541

Pharmacokinetics of ordinary and sustained-release lithium carbonate in manic patients after acute dosage.

D P Thornhill.   

Abstract

An ordinary and a sustained-release lithium carbonate preparation were administered acutely at equivalent dosage (1.80 g = 24.3 mmol) in a crossover fashion to manic patients. Serum lithium levels were determined by atomic absorption spectroscopy and pharmacokinetic parameters were calculated. Maximum mean serum levels of 1.13 mmol/l and 0.78 mmol/l were achieved at 6 h and 12 h respectively with the ordinary and sustained-release forms. The mean half-lives of absorption, redistribution and elimination were 0.78 h +/- 0.05 (SE), 5.06 h +/- 0.23, 26.8 h +/- 4.5 and 3.73 h +/- 0.37 (SE), 4.42 h +/- 0.28 and 25.6 h +/- 5.5 for the ordinary and sustained-release forms respectively. In healthy volunteers the ordinary preparation was completely absorbed but only 85% of the sustained-release form was absorbed in the manic subjects. Lithium ion distributed into two kinetic compartments and the final compartment appeared to correspond to total body water.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 365541     DOI: 10.1007/bf00560460

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

1.  Absorption of lithium following administration of slow-release and conventional preparations.

Authors:  S Tyrer; R P Hullin; N J Birch; J C Goodwin
Journal:  Psychol Med       Date:  1976-02       Impact factor: 7.723

2.  Relationship between serum lithium level and clinical response in acute mania treated with lithium.

Authors:  R F Prien; E M Caffey; C J Klett
Journal:  Br J Psychiatry       Date:  1972-04       Impact factor: 9.319

3.  Blood levels and management of lithium treatment.

Authors:  J L Crammer; R M Rosser; G Crane
Journal:  Br Med J       Date:  1974-09-14

4.  Prophylactic lithium: another therapeutic myth? An examination of the evidence to date.

Authors:  B Blackwell; M Shepherd
Journal:  Lancet       Date:  1968-05-04       Impact factor: 79.321

5.  Lithium retention and response.

Authors:  M Serry
Journal:  Lancet       Date:  1969-06-21       Impact factor: 79.321

Review 6.  Critique of studies of lithium salts in the treatment of mania.

Authors:  W K Shull; J D Sapira
Journal:  Am J Psychiatry       Date:  1970-08       Impact factor: 18.112

7.  Lithium carbonate: a clinical study.

Authors:  H Zall; P G Therman; J M Myers
Journal:  Am J Psychiatry       Date:  1968-10       Impact factor: 18.112

8.  Measuring measurin: problems of oral prolonged-action medications.

Authors:  L E Hollister
Journal:  Clin Pharmacol Ther       Date:  1972 Jan-Feb       Impact factor: 6.875

  8 in total
  5 in total

1.  First-dose pharmacokinetics of lithium carbonate in children and adolescents.

Authors:  Robert L Findling; Cornelia B Landersdorfer; Vivian Kafantaris; Mani Pavuluri; Nora K McNamara; Jon McClellan; Jean A Frazier; Linmarie Sikich; Robert Kowatch; Jacqui Lingler; Jon Faber; Perdita Taylor-Zapata; William J Jusko
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

2.  Formulation and in vitro-in vivo evaluation of sustained-release lithium carbonate tablets.

Authors:  K Ciftçi; Y Capan; O Oztürk; A A Hincal
Journal:  Pharm Res       Date:  1990-04       Impact factor: 4.200

3.  The influence of assay variability on pharmacokinetic parameter estimation.

Authors:  D A Graves; C S Locke; K T Muir; R P Miller
Journal:  J Pharmacokinet Biopharm       Date:  1989-10

4.  Distribution of lithium elimination rates in a selected population of psychiatric patients.

Authors:  D P Thornhill; S P Field
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 5.  Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring.

Authors:  Etienne Marc Grandjean; Jean-Michel Aubry
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.